Masimo shareholders today will decide on a bitter proxy fight between the company's founder and CEO Joe Kiani and Politan ...

Masimo Corp shareholders elected both director candidates proposed by veteran activist investor Quentin Koffey's hedge fund Politan Capital Management, in one of the most contentious boardroom battles ...

Joe Kiani, founder of a company that he built into billions of dollars of sales, was ousted from the board, according to an ...

Masimo Corporation (“Masimo” or the “Company ... their respective arguments in the shareholder fight.” 1 Represents a non-GAAP financial measure. Refer to the heading “Non-GAAP ...

Google's Wear OS will see health tracking upgrades courtesy of Masimo, the patent-holder responsible for blocking Apple Watch ...

Koffey was elected to Masimo’s board in June 2023 along with Politan-backed candidate Michelle Brennan, a former Johnson & Johnson executive. The hedge fund argued that Masimo’s $1 billion acquisition ...

Politan Capital Management (together with its affiliates, "Politan"), a 9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ: MASI), today commented on the outcome of the Company's ...

Masimo, which went public in 2007, is expected to generate $2.1 billion in revenue this year, according to the average estimate of analysts. Kiani has also become well known in Democrat Party circles ...

1. Published clinical studies on pulse oximetry and the benefits of Masimo SET ® can be found on our website at www.masimo.com. Comparative studies include independent and objective studies which ...

Details How Independent Third Parties and the Evidence in Legal Proceedings Have Consistently Refuted Masimo’s "Defensive ... the Board’s credibility: 1,2 "The board's various arguments ...

Reflecting continued confidence in Masimo’s business and strategy, the Company has materially raised its full-year GAAP consolidated EPS guidance range to $1.74-$1.89, and the non-GAAP ...

1 Masimo SET ® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, 2 improve CCHD screening in newborns 3 and, when used for continuous monitoring with ...